{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:02:22Z","timestamp":1792821742649,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:00:00Z","timestamp":1691798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:00:00Z","timestamp":1691798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Wujieping Medical Foundation of China","award":["20.6750.2021-04-37"],"award-info":[{"award-number":["20.6750.2021-04-37"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-023-01134-w","type":"journal-article","created":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T04:01:50Z","timestamp":1691812910000},"page":"5269-5279","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Somatic ARAF mutations in pediatric Langerhans cell histiocytosis: clinicopathologic, genetic and functional profiling"],"prefix":"10.1007","volume":"23","author":[{"given":"Rong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunqiao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodai","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,12]]},"reference":[{"issue":"9","key":"1134_CR1","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1056\/NEJMra1607548","volume":"379","author":"CE Allen","year":"2018","unstructured":"Allen CE, Merad M, McClain KL. Langerhans-Cell Histiocytosis. N Engl J Med. 2018;379(9):856\u201368.","journal-title":"N Engl J Med"},{"issue":"16","key":"1134_CR2","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1182\/blood.2019000934","volume":"135","author":"C Rodriguez-Galindo","year":"2020","unstructured":"Rodriguez-Galindo C, Allen CE. Langerhans cell histiocytosis. Blood. 2020;135(16):1319\u201331.","journal-title":"Blood"},{"issue":"9\u201310","key":"1134_CR3","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1242\/dmm.004010","volume":"2","author":"BA Degar","year":"2009","unstructured":"Degar BA, Rollins BJ. Langerhans cell histiocytosis: malignancy or inflammatory disorder doing a great job of imitating one? Dis Model Mech. 2009;2(9\u201310):436\u20139.","journal-title":"Dis Model Mech"},{"issue":"10","key":"1134_CR4","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/j.1365-4632.2009.04360.x","volume":"49","author":"Z Li","year":"2010","unstructured":"Li Z, Yanqiu L, Yan W, et al. Two case report studies of Langerhans cell histiocytosis with an analysis of 918 patients of Langerhans cell histiocytosis in literatures published in China. Int J Dermatol. 2010;49(10):1169\u201374.","journal-title":"Int J Dermatol"},{"issue":"10","key":"1134_CR5","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.5858\/arpa.2015-0199-RA","volume":"139","author":"CM Harmon","year":"2015","unstructured":"Harmon CM, Brown N. Langerhans cell histiocytosis: a clinicopathologic review and molecular pathogenetic update. Arch Pathol Lab Med. 2015;139(10):1211\u20134.","journal-title":"Arch Pathol Lab Med"},{"key":"1134_CR6","doi-asserted-by":"crossref","unstructured":"Gulati N, Allen CE. Langerhans cell histiocytosis: Version 2021. Hematol Oncol. 2021;39(Suppl 1):15\u201323.","DOI":"10.1002\/hon.2857"},{"issue":"1","key":"1134_CR7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bjh.13247","volume":"169","author":"ML Berres","year":"2015","unstructured":"Berres ML, Merad M, Allen CE. Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X? Br J Haematol. 2015;169(1):3\u201313.","journal-title":"Br J Haematol"},{"issue":"1","key":"1134_CR8","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/hon.2388","volume":"36","author":"LY Ballester","year":"2018","unstructured":"Ballester LY, Cantu MD, Lim KPH, et al. The use of BRAF V600E mutation-specific immunohistochemistry in pediatric Langerhans cell histiocytosis. Hematol Oncol. 2018;36(1):307\u201315.","journal-title":"Hematol Oncol"},{"issue":"25","key":"1134_CR9","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1200\/JCO.2015.65.9508","volume":"34","author":"S Heritier","year":"2016","unstructured":"Heritier S, Emile JF, Barkaoui MA, et al. BRAF mutation correlates with high-risk langerhans cell histiocytosis and increased resistance to first-line therapy. J Clin Oncol. 2016;34(25):3023\u201330.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1134_CR10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12185-020-02892-z","volume":"112","author":"M Kobayashi","year":"2020","unstructured":"Kobayashi M, Ando S, Kawamata T, et al. Clinical features and outcomes of adult Langerhans cell histiocytosis: a single-center experience. Int J Hematol. 2020;112(2):185\u201392.","journal-title":"Int J Hematol"},{"issue":"8","key":"1134_CR11","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1177\/1066896919855774","volume":"27","author":"X Liu","year":"2019","unstructured":"Liu X, Zhang Y, Zhou CX. High prevalence of BRAF V600E mutations in langerhans cell histiocytosis of head and neck in chinese patients. Int J Surg Pathol. 2019;27(8):836\u201343.","journal-title":"Int J Surg Pathol"},{"issue":"3","key":"1134_CR12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/hon.2293","volume":"35","author":"Y Sasaki","year":"2017","unstructured":"Sasaki Y, Guo Y, Arakawa F, et al. Analysis of the BRAFV600E mutation in 19 cases of Langerhans cell histiocytosis in Japan. Hematol Oncol. 2017;35(3):329\u201334.","journal-title":"Hematol Oncol"},{"issue":"1","key":"1134_CR13","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s13023-021-01912-3","volume":"16","author":"S Feng","year":"2021","unstructured":"Feng S, Han L, Yue M, et al. Frequency detection of BRAF V600E mutation in a cohort of pediatric langerhans cell histiocytosis patients by next-generation sequencing. Orphanet J Rare Dis. 2021;16(1):272.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"1134_CR14","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jaad.2017.05.059","volume":"78","author":"J Krooks","year":"2018","unstructured":"Krooks J, Minkov M, Weatherall AG. Langerhans cell histiocytosis in children: History, classification, pathobiology, clinical manifestations, and prognosis. J Am Acad Dermatol. 2018;78(6):1035\u201344.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1134_CR15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/pbc.24367","volume":"60","author":"R Haupt","year":"2013","unstructured":"Haupt R, Minkov M, Astigarraga I, et al. Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer. 2013;60(2):175\u201384.","journal-title":"Pediatr Blood Cancer"},{"key":"1134_CR16","doi-asserted-by":"crossref","unstructured":"Minkov M, Grois N, Heitger A, et al. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group. Klin Padiatr. 2000;212(4):139\u201344.","DOI":"10.1055\/s-2000-9667"},{"issue":"3","key":"1134_CR17","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/cncr.21985","volume":"107","author":"A Morimoto","year":"2006","unstructured":"Morimoto A, Ikushima S, Kinugawa N, et al. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: Results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study. Cancer. 2006;107(3):613\u20139.","journal-title":"Cancer"},{"issue":"25","key":"1134_CR18","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1182\/blood-2012-09-455774","volume":"121","author":"H Gadner","year":"2013","unstructured":"Gadner H, Minkov M, Grois N, et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013;121(25):5006\u201314.","journal-title":"Blood"},{"issue":"3","key":"1134_CR19","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/bjh.17243","volume":"192","author":"K Sakamoto","year":"2021","unstructured":"Sakamoto K, Morimoto A, Shioda Y, et al. Long-term complications in uniformly treated paediatric Langerhans histiocytosis patients disclosed by 12 years of follow-up of the JLSG-96\/02 studies. Br J Haematol. 2021;192(3):615\u201320.","journal-title":"Br J Haematol"},{"issue":"2","key":"1134_CR20","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s12185-018-2444-0","volume":"108","author":"A Morimoto","year":"2018","unstructured":"Morimoto A, Shioda Y, Imamura T, et al. Intensification of induction therapy and prolongation of maintenance therapy did not improve the outcome of pediatric Langerhans cell histiocytosis with single-system multifocal bone lesions: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study. Int J Hematol. 2018;108(2):192\u20138.","journal-title":"Int J Hematol"},{"issue":"11","key":"1134_CR21","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41568-018-0060-1","volume":"18","author":"Z Sondka","year":"2018","unstructured":"Sondka Z, Bamford S, Cole CG, et al. The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers. Nat Rev Cancer. 2018;18(11):696\u2013705.","journal-title":"Nat Rev Cancer"},{"issue":"W1","key":"1134_CR22","doi-asserted-by":"crossref","first-page":"W446","DOI":"10.1093\/nar\/gkab266","volume":"49","author":"R Steinhaus","year":"2021","unstructured":"Steinhaus R, Proft S, Schuelke M, et al. MutationTaster2021. Nucleic Acids Res. 2021;49(W1):W446\u201351.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"1134_CR23","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/nprot.2009.86","volume":"4","author":"P Kumar","year":"2009","unstructured":"Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4(7):1073\u201381.","journal-title":"Nat Protoc"},{"issue":"16","key":"1134_CR24","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1093\/bioinformatics\/btv195","volume":"31","author":"Y Choi","year":"2015","unstructured":"Choi Y, Chan AP. PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels. Bioinformatics. 2015;31(16):2745\u20137.","journal-title":"Bioinformatics"},{"issue":"1","key":"1134_CR25","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1186\/s12859-017-1862-y","volume":"18","author":"M Ferlaino","year":"2017","unstructured":"Ferlaino M, Rogers MF, Shihab HA, et al. An integrative approach to predicting the functional effects of small indels in non-coding regions of the human genome. BMC Bioinformatics. 2017;18(1):442.","journal-title":"BMC Bioinformatics"},{"issue":"D1","key":"1134_CR26","doi-asserted-by":"crossref","first-page":"D886","DOI":"10.1093\/nar\/gky1016","volume":"47","author":"P Rentzsch","year":"2019","unstructured":"Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res. 2019;47(D1):D886\u201394.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"1134_CR27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13073-020-00775-w","volume":"12","author":"S Li","year":"2020","unstructured":"Li S, van der Velde KJ, de Ridder D, et al. CAPICE: a computational method for Consequence-Agnostic Pathogenicity Interpretation of Clinical Exome variations. Genome Med. 2020;12(1):75.","journal-title":"Genome Med"},{"issue":"8","key":"1134_CR28","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1101\/gr.3715005","volume":"15","author":"A Siepel","year":"2005","unstructured":"Siepel A, Bejerano G, Pedersen JS, et al. Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. Genome Res. 2005;15(8):1034\u201350.","journal-title":"Genome Res"},{"issue":"1","key":"1134_CR29","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1101\/gr.097857.109","volume":"20","author":"KS Pollard","year":"2010","unstructured":"Pollard KS, Hubisz MJ, Rosenbloom KR, Siepel A. Detection of nonneutral substitution rates on mammalian phylogenies. Genome Res. 2010;20(1):110\u201321.","journal-title":"Genome Res"},{"issue":"1","key":"1134_CR30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","volume":"19","author":"MM Li","year":"2017","unstructured":"Li MM, Datto M, Duncavage EJ, et al. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017;19(1):4\u201323.","journal-title":"J Mol Diagn"},{"issue":"4","key":"1134_CR31","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1084\/jem.20130977","volume":"211","author":"ML Berres","year":"2014","unstructured":"Berres ML, Lim KP, Peters T, et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014;211(4):669\u201383.","journal-title":"J Exp Med"},{"issue":"4","key":"1134_CR32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033891","volume":"7","author":"T Satoh","year":"2012","unstructured":"Satoh T, Smith A, Sarde A, et al. B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease. PLoS ONE. 2012;7(4): e33891.","journal-title":"PLoS ONE"},{"issue":"2","key":"1134_CR33","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1365-2141.2011.08915.x","volume":"156","author":"G Badalian-Very","year":"2012","unstructured":"Badalian-Very G, Vergilio JA, Degar BA, Rodriguez-Galindo C, Rollins BJ. Recent advances in the understanding of Langerhans cell histiocytosis. Br J Haematol. 2012;156(2):163\u201372.","journal-title":"Br J Haematol"},{"issue":"10","key":"1134_CR34","doi-asserted-by":"crossref","first-page":"643","DOI":"10.5435\/JAAOS-22-10-643","volume":"22","author":"MR DiCaprio","year":"2014","unstructured":"DiCaprio MR, Roberts TT. Diagnosis and management of Langerhans cell histiocytosis. J Am Acad Orthop Surg. 2014;22(10):643\u201352.","journal-title":"J Am Acad Orthop Surg"},{"issue":"7","key":"1134_CR35","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/ncb2507","volume":"14","author":"X Gan","year":"2012","unstructured":"Gan X, Wang J, Wang C, et al. PRR5L degradation promotes mTORC2-mediated PKC-delta phosphorylation and cell migration downstream of Galpha12. Nat Cell Biol. 2012;14(7):686\u201396.","journal-title":"Nat Cell Biol"},{"issue":"8","key":"1134_CR36","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","volume":"7","author":"Consortium APG","year":"2017","unstructured":"Consortium APG. AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov. 2017;7(8):818\u201331.","journal-title":"Cancer Discov"},{"issue":"20","key":"1134_CR37","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1182\/blood-2013-06-511139","volume":"123","author":"DS Nelson","year":"2014","unstructured":"Nelson DS, Quispel W, Badalian-Very G, et al. Somatic activating ARAF mutations in Langerhans cell histiocytosis. Blood. 2014;123(20):3152\u20135.","journal-title":"Blood"},{"issue":"19","key":"1134_CR38","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood-2014-05-577825","volume":"124","author":"R Chakraborty","year":"2014","unstructured":"Chakraborty R, Hampton OA, Shen X, et al. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood. 2014;124(19):3007\u201315.","journal-title":"Blood"},{"issue":"7","key":"1134_CR39","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/PAS.0000000000001057","volume":"42","author":"LM McGinnis","year":"2018","unstructured":"McGinnis LM, Nybakken G, Ma L, Arber DA. Frequency of MAP2K1, TP53, and U2AF1 mutations in BRAF-mutated Langerhans Cell histiocytosis: further characterizing the genomic landscape of LCH. Am J Surg Pathol. 2018;42(7):885\u201390.","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"1134_CR40","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2159-8290.CD-15-0913","volume":"6","author":"EL Diamond","year":"2016","unstructured":"Diamond EL, Durham BH, Haroche J, et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov. 2016;6(2):154\u201365.","journal-title":"Cancer Discov"},{"issue":"26","key":"1134_CR41","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1038\/onc.2012.330","volume":"32","author":"AP Rebocho","year":"2013","unstructured":"Rebocho AP, Marais R. ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers. Oncogene. 2013;32(26):3207\u201312.","journal-title":"Oncogene"},{"issue":"7","key":"1134_CR42","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/s41591-019-0479-2","volume":"25","author":"D Li","year":"2019","unstructured":"Li D, March ME, Gutierrez-Uzquiza A, et al. ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor. Nat Med. 2019;25(7):1116\u201322.","journal-title":"Nat Med"},{"issue":"10","key":"1134_CR43","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1182\/blood-2014-05-577361","volume":"124","author":"NA Brown","year":"2014","unstructured":"Brown NA, Furtado LV, Betz BL, et al. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood. 2014;124(10):1655\u20138.","journal-title":"Blood"},{"issue":"21","key":"1134_CR44","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1182\/blood-2016-08-733790","volume":"128","author":"R Chakraborty","year":"2016","unstructured":"Chakraborty R, Burke TM, Hampton OA, et al. Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. Blood. 2016;128(21):2533\u20137.","journal-title":"Blood"},{"issue":"1","key":"1134_CR45","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12943-017-0690-z","volume":"16","author":"S Heritier","year":"2017","unstructured":"Heritier S, Helias-Rodzewicz Z, Chakraborty R, et al. New somatic BRAF splicing mutation in Langerhans cell histiocytosis. Mol Cancer. 2017;16(1):115.","journal-title":"Mol Cancer"},{"issue":"6","key":"1134_CR46","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/gcc.22247","volume":"54","author":"DS Nelson","year":"2015","unstructured":"Nelson DS, van Halteren A, Quispel WT, et al. MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis. Genes Chromosomes Cancer. 2015;54(6):361\u20138.","journal-title":"Genes Chromosomes Cancer"},{"issue":"36","key":"1134_CR47","doi-asserted-by":"crossref","first-page":"26575","DOI":"10.1074\/jbc.M702429200","volume":"282","author":"A Baljuls","year":"2007","unstructured":"Baljuls A, Mueller T, Drexler HC, Hekman M, Rapp UR. Unique N-region determines low basal activity and limited inducibility of A-RAF kinase: the role of N-region in the evolutionary divergence of RAF kinase function in vertebrates. J Biol Chem. 2007;282(36):26575\u201390.","journal-title":"J Biol Chem"},{"issue":"1","key":"1134_CR48","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1084\/jem.20161881","volume":"215","author":"B Hogstad","year":"2018","unstructured":"Hogstad B, Berres ML, Chakraborty R, et al. RAF\/MEK\/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. J Exp Med. 2018;215(1):319\u201336.","journal-title":"J Exp Med"},{"issue":"1","key":"1134_CR49","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s12185-016-1993-3","volume":"104","author":"A Morimoto","year":"2016","unstructured":"Morimoto A, Shioda Y, Imamura T, et al. Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study. Int J Hematol. 2016;104(1):99\u2013109.","journal-title":"Int J Hematol"},{"issue":"3","key":"1134_CR50","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jamaoncol.2017.5029","volume":"4","author":"EL Diamond","year":"2018","unstructured":"Diamond EL, Subbiah V, Lockhart AC, et al. Vemurafenib for BRAF V600-Mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, Phase 2. Open-label VE-BASKET Study JAMA Oncol. 2018;4(3):384\u20138.","journal-title":"Open-label VE-BASKET Study JAMA Oncol"},{"issue":"7749","key":"1134_CR51","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41586-019-1012-y","volume":"567","author":"EL Diamond","year":"2019","unstructured":"Diamond EL, Durham BH, Ulaner GA, et al. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019;567(7749):521\u20134.","journal-title":"Nature"},{"issue":"15","key":"1134_CR52","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood-2018-10-878363","volume":"133","author":"OS Eckstein","year":"2019","unstructured":"Eckstein OS, Visser J, Rodriguez-Galindo C, Allen CE. Clinical responses and persistent BRAF V600E(+) blood cells in children with LCH treated with MAPK pathway inhibition. Blood. 2019;133(15):1691\u20134.","journal-title":"Blood"},{"issue":"31","key":"1134_CR53","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1200\/JCO.19.00456","volume":"37","author":"J Donadieu","year":"2019","unstructured":"Donadieu J, Larabi IA, Tardieu M, et al. Vemurafenib for refractory multisystem Langerhans cell Histiocytosis in children: an international observational study. J Clin Oncol. 2019;37(31):2857\u201365.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1134_CR54","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","volume":"373","author":"DM Hyman","year":"2015","unstructured":"Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373(8):726\u201336.","journal-title":"N Engl J Med"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01134-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-023-01134-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01134-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T16:09:29Z","timestamp":1702742969000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-023-01134-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,12]]},"references-count":54,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1134"],"URL":"https:\/\/doi.org\/10.1007\/s10238-023-01134-w","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,12]]},"assertion":[{"value":"18 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors Y.G., L.H., Y.S. and Z.C. are employed by GrandOmics (Beijing, China). All authors declared no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed according to the Declaration of Helsinki, and the collection of tissues or blood samples from patients was obtained with patient-informed consent (from their guardians) under approval by the research ethics committee of the Children\u2019s Hospital of Capital Institute of Pediatrics (Identifier: SHERLLM2020005). All patients provided written informed consent for publication of their cases.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}